Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with…. Sold as Ziextenzo. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Pegfilgrastim-Bmez (sold as Ziextenzo), first approved Nov 4, 2019, with 0 new uses approved and 1 published complete response letter.
First approved: Nov 4, 2019
Applications: 1
New uses approved: 0
Complete response letters: 1
Medicare spending, 2025: $573K
First approved in the EU: Aug 22, 2002
First approved in Japan: Sep 26, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 61 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
G-LastaA drug with a new indication for the mobilization of hematopoietic stem cells to the peripheral blood for autologous hematopoietic stem cell transplantation. · Kyowa Kirin Co., Ltd. · May 17, 2024
G-LastaA drug with a new indication and a new dosage for the mobilization of hematopoietic stem cell to the peripheral blood for allogenic peripheral blood stem… · Kyowa Kirin Co., Ltd. · Feb 25, 2022
G-Lasta, new ingredientA drug with a new active ingredient indicated for decreasing the incidence of cancer chemotherapy- induced febrile neutropenia. · Kyowa Hakko Kirin Co., Ltd. · Sep 26, 2014
Clinical Trials
11 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
LA-EP2006Clinical Pharmacology, Product Quality, Container Label And Carton Labeling
Approved
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
